Certara Inc. (CERT): Price and Financial Metrics

Certara Inc. (CERT): $20.96

0.95 (+4.75%)

POWR Rating

Component Grades













Add CERT to Watchlist
Sign Up

Industry: Biotech



in industry


  • CERT scores best on the Growth dimension, with a Growth rank ahead of 95.96% of US stocks.
  • The strongest trend for CERT is in Growth, which has been heading up over the past 179 days.
  • CERT's current lowest rank is in the Value metric (where it is better than 11.25% of US stocks).

CERT Stock Summary

  • Certara Inc's stock had its IPO on December 11, 2020, making it an older stock than merely 1.54% of US equities in our set.
  • The price/operating cash flow metric for Certara Inc is higher than 91.71% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 12.65, Certara Inc has a higher such ratio than 88.47% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Certara Inc are BMBL, UAVS, FUBO, IRTC, and SVFD.
  • Visit CERT's SEC page to see the company's official filings. To visit the company's web site, go to www.certara.com.

CERT Valuation Summary

  • CERT's price/sales ratio is 21.1; this is 455.26% higher than that of the median Healthcare stock.
  • Over the past 38 weeks, CERT's EV/EBIT ratio has gone down 534.2.
  • Over the past 38 weeks, CERT's price/earnings ratio has gone up 547.5.

Below are key valuation metrics over time for CERT.

Stock Date P/S P/B P/E EV/EBIT
CERT 2021-08-31 21.1 6.1 -103.9 -207.3
CERT 2021-08-30 20.7 6.0 -101.8 -203.2
CERT 2021-08-27 20.6 6.0 -101.6 -202.7
CERT 2021-08-26 19.8 5.8 -97.6 -194.8
CERT 2021-08-25 19.5 5.7 -96.2 -192.0
CERT 2021-08-24 19.3 5.6 -94.9 -189.5

CERT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CERT has a Quality Grade of C, ranking ahead of 37.95% of graded US stocks.
  • CERT's asset turnover comes in at 0.211 -- ranking 481st of 561 Business Services stocks.
  • 500 - Internal server error

The table below shows CERT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.211 0.586 -0.07

CERT Price Target

For more insight on analysts targets of CERT, see our CERT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.50 Average Broker Recommendation 1.3 (Strong Buy)

CERT Stock Price Chart Interactive Chart >

Price chart for CERT

CERT Price/Volume Stats

Current price $20.96 52-week high $45.48
Prev. close $20.01 52-week low $16.17
Day low $20.14 Volume 318,300
Day high $21.04 Avg. volume 629,378
50-day MA $20.13 Dividend yield N/A
200-day MA $27.82 Market Cap 3.35B

Certara Inc. (CERT) Company Bio

Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.

CERT Latest News Stream

Event/Time News Detail
Loading, please wait...

CERT Latest Social Stream

Loading social stream, please wait...

View Full CERT Social Stream

Latest CERT News From Around the Web

Below are the latest news stories about Certara Inc that investors may wish to consider to help them evaluate CERT as an investment opportunity.

U.S. FDA Licenses Certara’s Immunogenicity Simulator

Affirms the advancements of innovative biosimulation technology and its growing impact in R&DPRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics. Certara’s IG Simulator predicts the immune response of therapeutics in development, which is important

Yahoo | February 23, 2022

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

Asserts Certara’s leadership in advancing the development and approval of new drugs for patientsPRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received by Certara’s customers in 2021, excluding diagnostic agents. This is the 8th consecutive year that Certara’s customers, who use

Yahoo | February 15, 2022

Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022

PRINCETON, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Tuesday, March 1st, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for inte

Yahoo | February 8, 2022

Certara Looks Positioned For Increased Growth In 2022

A Quick Take On Certara Certara (CERT) went public in December 2020, raising approximately $337 million in an upsized IPO that priced at $23.00 per share. The firm provides biosimulation software for biopharmaceutical firms and drug regulatory agencies worldwide. While I can’t discount future pandemic variants and their negative effects...

Donovan Jones on Seeking Alpha | February 2, 2022

Bell Bank Buys Vanguard Total Stock Market ETF, Vanguard S&P 500 ETF, Ares Capital Corp, ...

Investment company Bell Bank (Current Portfolio) buys Vanguard Total Stock Market ETF, Vanguard S&P 500 ETF, Ares Capital Corp, Hanesbrands Inc, SPDR Portfolio S&P 500 High Dividend ETF, sells Utilities Select Sector SPDR ETF, MetLife Inc, Conagra Brands Inc, Healthcare Services Group Inc, Gentex Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bell Bank.

Yahoo | February 1, 2022

Read More 'CERT' Stories Here

CERT Price Returns

1-mo 10.37%
3-mo -14.13%
6-mo -25.75%
1-year -20.33%
3-year N/A
5-year N/A
YTD -26.25%
2021 -15.72%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7531 seconds.